Cipla is on track to launch key products, such as gAdvair, gAbraxane, gRevlimid and three peptide products over FY23-24, it said, adding that the US sales run-rate will improve from H2FY23, and barring COVID-19, sales performance in India continues to be robust. The brokerage firm expects a revenue CAGR of 13 per cent, an EBITDA CAGR of 21 per cent and a PAT CAGR of 28 per cent over FY22-24E.
10 stks that got upgrades & downgrades from MOSL post Q4 results
As all major companies have already announced their Q4 results, brokerage firm Motilal Oswal has upgraded and downgraded the estimated FY24 earnings of several stocks.
June 3, 2023